Quantcast
Channel: WN.com - Articles related to U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia
Viewing all articles
Browse latest Browse all 270

Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics (H Lundbeck A/S)

$
0
0
(Source: H Lundbeck A/S) April 7, 2014 Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics Valby, 2014-04-07 12:00 CEST (GLOBE NEWSWIRE) -- Once-monthly Abilify Maintena® demonstrated a 10-fold reduction in hospitalisation rates when comparing the same patients with their previous standard of care with oral antipsychotics in a mirror-image study design (2.7 percent vs 27.1 percent respectively, Once-monthly Abilify Maintena®was well tolerated with rates of treatment emergent adverse events similar to the favourable tolerability profile oforal Abilify® Reducing the risk...

Viewing all articles
Browse latest Browse all 270

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>